Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Centre Leon Berard has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are split between 2 distinct examiners, meaning each examiner is responsible for 1 matter. The cases are also located in 2 distinct art units, indicating that the company's current patent activity covers different technical niches within the biotech sector. This distribution requires a prosecution strategy that accounts for the specific technical standards of each unit.
SHIM, DAVID M. is the busiest examiner for the portfolio, currently managing 1 pending office action. Because the 2 pending office actions are divided among 2 distinct examiners and 2 distinct art units, the company's prosecution efforts are not centralized. This distribution requires the company to tailor its approach to the specific standards and expectations of 2 different examiners in 2 different technical divisions. Practitioners should coordinate across these 2 distinct art units to ensure that arguments remain consistent while addressing the specific technical requirements of each pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
| SABILA, MERCY HELLEN | 1 | 57.5% | +45.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760024 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | SABILA, MERCY HELLEN | 126d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760024 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | SABILA, MERCY HELLEN | 126d overdue |
| 18699257 | Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699257 | Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma | SHIM, DAVID M. | 1626 | §103§112DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 17760024 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | SABILA, MERCY HELLEN | 1654 | §103§112 | Non-Final OA | 126d overdue | Pending | Aug 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Leon Berard has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David M. Shim has the most, with 1 of Centre Leon Berard's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
